Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding

NCT ID: NCT02755324

Last Updated: 2020-11-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 17 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-10-27
• Study Completion Date: 2019-01-21

Brief Summary

Groups of 3 or 7 volunteers will be exposed to a predetermined number of male Schistosoma mansoni cercariae until 10 volunteers are found infected.

Conditions

Schistosomiasis; Schistosoma Mansoni

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Intervention

Volunteers will be exposed to escalating doses of male Schistosoma mansoni cercariae

Group Type: EXPERIMENTAL

male Schistosoma mansoni cercariae

Intervention Type: BIOLOGICAL

Viable male Schistosoma mansoni cercariae of the Puerto Rican strain

Interventions

male Schistosoma mansoni cercariae

Viable male Schistosoma mansoni cercariae of the Puerto Rican strain

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Subject is aged ≥ 18 and ≤ 45 years and in good health.

2. Subject has adequate understanding of the procedures of the study and agrees to abide strictly thereby.

3. Subject is able to communicate well with the investigator, is available to attend all study visits.

4. Subject will remain within Europe (excluding Corsica) during the study period and is reachable by mobile telephone from week 3 to week 12 of the study period.

5. Subject agrees to refrain from blood donation throughout the study period.

6. For female subjects: subject agrees to use adequate contraception and not to breastfeed for the duration of study.

7. Subject has signed informed consent.

Exclusion Criteria

1. Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, renal, hepatic, neurological, dermatological, endocrine, malignant, haematological, infectious, immune-deficient, psychiatric and other disorders, which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results. These include, but are not limited to, any of the following:

• body weight <50 kg or Body Mass Index (BMI) <18.0 or >30.0 kg/m2 at screening;
• positive HIV, hepatitis B or hepatitis C screening tests;
• the use of immune modifying drugs within three months prior to study onset (inhaled and topical corticosteroids and oral anti-histamines exempted) or expected use of such during the study period;
• history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years;
• any history of treatment for severe psychiatric disease by a psychiatrist in the past year;
• history of drug or alcohol abuse interfering with normal social function in the period of one year prior to study onset.
• Any clinically significant abnormalities (including extended QT interval) on electrocardiogram

2. The chronic use of any drug known to interact with praziquantel, or artesunate or lumefantrine metabolism (e.g. phenytoin, carbamazepine, phenobarbital, primidon, dexamethasone, rifampicin, cimetidine, flecainide, metoprolol, imipramine, amitriptyline, clomipramine, class I and III anti-arrythmics, antipsychotics, antidepressants, macrolides, fluoroquinolones, imidazole- and triazole antimycotics, antihistamines) Because lumefantrine may cause extension of QT-time, chronic use of drugs with effect on QT interval are excluded from the study.

3. For female subjects: positive urine pregnancy test at screening.

4. Any history of schistosomiasis or treatment for schistosomiasis.

5. Positive serology for schistosomiasis or elevated serum or urine circulating anodic antigen or positive Schistosoma serology at baseline.

6. Known hypersensitivity to or contra-indications (including co-medication) for use of praziquantel or, artesunate or lumefantrine.

7. Being an employee or student of the department of parasitology or infectious diseases of the Leiden University Medical Center.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Leiden University

OTHER

Sponsor Role: lead

Responsible Party

Meta Roestenberg

MD, PhD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Meta Roestenberg

Role: PRINCIPAL_INVESTIGATOR

LUMC

Locations

Leiden University Medical Center

Leiden, , Netherlands

Countries

Netherlands

References

Langenberg MCC, Hoogerwerf MA, Janse JJ, van Lieshout L, Corstjens PLAM, Roestenberg M; CoHSI clinical trial team. Katayama Syndrome Without Schistosoma mansoni Eggs. Ann Intern Med. 2019 May 21;170(10):732-733. doi: 10.7326/L18-0438. Epub 2019 Jan 8. No abstract available.

Reference Type: RESULT

PMID: 30615787 (View on PubMed)

Langenberg MCC, Hoogerwerf MA, Koopman JPR, Janse JJ, Kos-van Oosterhoud J, Feijt C, Jochems SP, de Dood CJ, van Schuijlenburg R, Ozir-Fazalalikhan A, Manurung MD, Sartono E, van der Beek MT, Winkel BMF, Verbeek-Menken PH, Stam KA, van Leeuwen FWB, Meij P, van Diepen A, van Lieshout L, van Dam GJ, Corstjens PLAM, Hokke CH, Yazdanbakhsh M, Visser LG, Roestenberg M. A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics. Nat Med. 2020 Mar;26(3):326-332. doi: 10.1038/s41591-020-0759-x. Epub 2020 Feb 17.

Reference Type: RESULT

PMID: 32066978 (View on PubMed)

Other Identifiers

CoHSI1

Identifier Type: -

Identifier Source: org_study_id